Humacyte, Inc. (HUMA): Total Liabilities
$113.26M
As of 2025-12-31
$106.83M
As of 2026-06-30
+9.0%
3-year compound annual growth
+25.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $113.26M | -40.6% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $190.54M | +66.2% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $114.68M | +31.2% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $87.37M | -46.8% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $164.36M | +356.3% | 2023-03-24, Balance as of period end |
| 2020-12-31 | $36.02M | n/a | 2022-03-29, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Humacyte, Inc. (HUMA) | 2025-12-31 | $113.26M | -40.6% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $34.99M | -64.7% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $50.77M | -50.2% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $8.71M | +16.8% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $138.49M | +193.5% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $286.49M | +310.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $343.43M | +10.8% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $38.99M | +82.0% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $55.68M | +5.4% |
Compare HUMA, ALGS, OTLK, DYAI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗